Actinium Pharmaceuticals Inc.

United States of America

 
Total IP 131
Total IP Rank # 9,938
IP Activity Score 2.9/5.0    113
IP Activity Rank # 6,086
Stock Symbol
ISIN US00507W1071
Market Cap. 136M  (USD)
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

54 2
26 2
46 0
1
 
Last Patent 2025 - Methods for treating cd33-positi...
First Patent 1991 - Radioimmunotherapy using .alpha....
Last Trademark 2022 - ACTINIUM PHARMACEUTICALS
First Trademark 2021 - AVCURI

Industry (Nice Classification)

Latest Inventions, Goods, Services

2024 Invention Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimm...
Invention Methods for treatment of patients with myelodysplastic syndromes. Methods for treating a prolife...
Invention Combination therapies for the treatment of cd33-positive hematological malignancies harboring mut...
Invention Multi-arm bifunctional chelators. Provided are new multi-arm bifunctional chelators for use in th...
Invention Humanized anti-cd45 antibodies. Provided are humanized anti-human CD45 antibodies and pharmaceut...
Invention Calreticulin nanobodies. Provided are nanobodies that bind human calreticulin, fusion proteins in...
Invention Bifunctional chelators and conjugates. Provided are new bifunctional chelators for use in the ma...
Invention Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based ...
2023 Invention Her3 radioimmunotherapy for the treatment of solid cancers. Provided are compositions and methods...
Invention Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha- emitting radioim...
Invention Bifunctional chelators and conjugates. Provided are new bifunctional chelators for use in the man...
Invention Humanized anti-cd45 antibodies. Provided are humanized anti-human CD45 antibodies or antibody fra...
Invention Humanized anti-cd45 antibodies. Provided are humanized anti-human CD45 antibodies and pharmaceuti...
Invention Calreticulin nanobodies. Provided are nanobodies that bind human calreticulin, fusion proteins i...
Invention Grp78 nanobodies. Provided are nanobodies that recognize human cell surface GRP78 protein, pharma...
Invention Her3 nanobodies. Provided are anti-huHER3 nanobody or a fusion proteins, including an anti-huHER3...
Invention Methods for treating cd33-positive hematological malignancies. Provided are methods for treating...
Invention Methods for treating cd33-positive hematological malignancies. Provided are methods for treating ...
2022 Invention Her3 radioimmunotherapy for the treatment of solid cancers. Provided are compositions and method...
Invention Radioimmunoconjugates targeting grp78 for use in the treatment of cancer. Methods for treating c...
Invention Radioconjugates targeting grp78 for use in the treatment of cancer. Methods for treating cancers ...
Invention Radioimmunoconjugates targeting grp78 for use in the treatment of cancer. Methods for treating ca...
G/S Medicinal preparations for use in oncology Pharmaceutical preparations and substances for the tre...
Invention Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer. Methods fo...
Invention Radioconjugates targeting cd33 in the treatment of cancers. The invention provides compositions a...
Invention Radioimmunoconjugates targeting calreticulin for use in the treatment of cancer. Methods for tre...
Invention Radioimmunoconjugates targeting calreticulin for use in the treatment of cancer. Methods for trea...
Invention Radioconjugates targeting cd33 in the treatment of cancers. The invention provides compositions ...
G/S Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in a prepara...
G/S Pharmaceutical preparations for use in oncology Pharmaceutical preparations for use in a preparat...
Invention Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer. Provided are compos...
Invention Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer. Provided are composi...
Invention Combination radioimmunotherapy and cd47 blockade in the treatment of cancer. Provided are compos...
Invention Combination radioimmunotherapy and cd47 blockade in the treatment of cancer. Provided are composi...
Invention Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells. Prov...
Invention Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells. Provi...
Invention Low dose antibody-based methods for treating hematologic malignancies. This invention provides a...
2021 Invention Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers. Compositions and...
Invention Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225....
Invention Dr5 radioimmunotherapy in the treatment of solid cancers. Methods for treating a proliferative d...
2020 Invention Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof. Compositions and methods u...
Invention Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hema...
2018 Invention Combination therapy for treatment of a hematological disease. Methods for treating a hematologic...